Captrust Financial Advisors lessened its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 3.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 47,433 shares of the insurance provider's stock after selling 1,888 shares during the quarter. Captrust Financial Advisors' holdings in Humana were worth $12,034,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FPC Investment Advisory Inc. acquired a new position in Humana during the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC purchased a new stake in Humana during the fourth quarter valued at approximately $30,000. LFA Lugano Financial Advisors SA lifted its position in Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. OFI Invest Asset Management bought a new stake in shares of Humana in the 4th quarter valued at about $33,000. Finally, Transce3nd LLC purchased a new position in shares of Humana during the 4th quarter valued at approximately $38,000. Institutional investors and hedge funds own 92.38% of the company's stock.
Analyst Ratings Changes
Several brokerages recently weighed in on HUM. Oppenheimer raised their target price on shares of Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a report on Thursday, May 1st. Barclays raised their price objective on Humana from $270.00 to $322.00 and gave the stock an "equal weight" rating in a research note on Friday, April 11th. Raymond James raised Humana from a "market perform" rating to an "outperform" rating and set a $315.00 target price on the stock in a report on Thursday, May 1st. Royal Bank of Canada restated an "outperform" rating and issued a $283.00 target price on shares of Humana in a report on Wednesday, February 12th. Finally, Truist Financial lowered their price target on Humana from $325.00 to $305.00 and set a "hold" rating on the stock in a research report on Monday. Seventeen research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $286.81.
View Our Latest Analysis on HUM
Humana Trading Down 6.7%
Shares of HUM traded down $16.90 during trading hours on Tuesday, hitting $235.96. 1,472,414 shares of the stock were exchanged, compared to its average volume of 1,743,353. The firm has a market capitalization of $28.48 billion, a P/E ratio of 23.71, a price-to-earnings-growth ratio of 2.05 and a beta of 0.49. The business has a 50-day moving average of $265.02 and a 200-day moving average of $270.41. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46.
Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping analysts' consensus estimates of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to analysts' expectations of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. The firm's revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the company earned $7.23 EPS. On average, research analysts expect that Humana Inc. will post 16.47 EPS for the current year.
Humana Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.50%. The ex-dividend date is Friday, June 27th. Humana's dividend payout ratio is presently 25.04%.
About Humana
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
See Also
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
